Hiltonol® plus Dendritic
Cell Vaccine for Recurrent Glioblastoma
April, 2007. Oncovir is pleased to announce the opening
of a new clinical trial of Hiltonol® plus a dendritic cell vaccine targeting specific brain tumor antigens in patients
with recurrent glioblastoma. The study is being conducted by Dr. Hideho Okada at the University of Pittsburgh Medical Center.
Hiltonol® (Poly-ICLC) plus Temodar® Treatment
of Glioblastoma, A Multicenter Clinical Trial
January, 2006. Oncovir is pleased to announce the opening of a new multicenter
clinical trial to be conducted in collaboration with the prestigious NABTT consortium. Patients with newly diagnosed glioblastoma
will be treated with a combination of Hiltonol (Poly-ICLC) and Temodar® chemotherapy.
Hiltonol™ (Poly-ICLC) Treatment of Brain Tumors
April, 2003. Oncovir is cosponsoring
two multicenter phase II clinical trials of treatment with its experimental product, Hiltonol™ (poly-ICLC) for patients
with malignant brain tumors. The trials are being conducted by the prestigious North American Brain Tumor Consortium (NABTC).
Hiltonol™(Poly-ICLC) Treatment in a Smallpox Model
In a presentation at the International
Conference on Antiviral Research in Savannah, Dr. Samuel Baron of Galveston reported marked protection by Hiltonol™
in an otherwise lethal model of disseminated vaccinia poxvirus infection in mice. A single injection of Hiltonol™ provided
80 to 100% protection against mortality due to disseminated virus for as long as 8 days, and a greater than 100-fold inhibition
in organ viral load. The vaccinia virus is also the basis of the current smallpox live-virus vaccines, but treatment with
Hiltonol™ did not prevent the development of long term immunity to vaccination. The authors infer that treatment with
a low, non-toxic dose of Hiltonol™ at the same time as vaccination of humans may provide immediate protection against
smallpox and may reduce vaccine complications, while not inhibiting the immune response to vaccination.